CALCR
ENSG00000004948
Target class
GPCR
Chromosome
7
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- CALCR
- Gene name
- Calcitonin receptor
- Gene symbol
- CALCR
- Protein name
- Calcitonin receptor (CT-R)
- CTR
- CT-R
- Gene biotype
- Protein coding
- Gene family
- Calcitonin receptors|MicroRNA protein coding host genes
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 1
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 3.19
- Tissue specificity (Gini)
- 0.834
- Tissue specificity (tau)
- 0.972
- KEGG gene identifiers
- hsa:799
- R-HSA-418555
- R-HSA-419812
- End position
- 93575738
- Start position
- 93424486
- Chromosome
- 7
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- Cell Junctions
- Centriolar satellite
- Vesicles
Publication evidence
- PubMed 35324283
- Tissue specificity (tau)
- 0.972319
- Expression inequality (Gini)
- 0.833851
Expression in transcripts per million
- Brain - Hypothalamus
- 3.19
- Testis
- 0.94
- Kidney - Medulla
- 0.79
- Kidney - Cortex
- 0.78
- Pituitary
- 0.28
Expression in transcripts per million
- Brain - Hypothalamus3.19
- Testis0.94
- Kidney - Medulla0.79
- Kidney - Cortex0.78
- Pituitary0.28
- Brain - Nucleus accumbens (basal ganglia)0.26
- Muscle - Skeletal0.18
- Brain - Amygdala0.12
- Nerve - Tibial0.12
- Brain - Spinal cord (cervical c-1)0.1
- Adipose - Subcutaneous0.1
- Brain - Substantia nigra0.09
- Brain - Anterior cingulate cortex (BA24)0.08
- Artery - Aorta0.08
- Brain - Hippocampus0.07
- Lung0.07
- Brain - Frontal Cortex (BA9)0.07
- Breast - Mammary Tissue0.07
- Adipose - Visceral (Omentum)0.05
- Artery - Tibial0.05
- Artery - Coronary0.05
- Brain - Cortex0.04
- Small Intestine - Terminal Ileum0.03
- Esophagus - Gastroesophageal Junction0.02
- Brain - Caudate (basal ganglia)0.02
And 29 more, listed on the interactive page.
- GO:0007189
- GO:0010628
- GO:0050850
- GO:0051384
- GO:0051897
- GO:0070374
- GO:0097646
- GO:0097647
- GO:0141163
- GO:0150059
- GO:0150060
- GO:0150061
- GO:1904645
- GO:0005886
- GO:0150056
- GO:0150057
- GO:0150058
- GO:0001540
- GO:0001635
- GO:0004948
- GO:0005515
- GO:0032841
- GO:0097642
- GO:0097643
Related records
Trials (201)
- A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment
- A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
- A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
- A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes
- A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes
- A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes
- A Prospective Real World Study of Rimegepant in the Treatment of Migraine
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
- A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study
- A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area
- A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body
- A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
- A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function
- A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
- A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity
- A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity
- A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
Drugs (12)
- Adrenomedullin
- Cagrilintide
- Calcitonin Calcitonin receptor agonist
- Calcitonin human Calcitonin receptor agonist
- Calcitonin salmon Calcitonin receptor agonist
- Davalintide Amylin receptor AMY1, CALCR/RAMP1 agonist
- Davalintide acetate Amylin receptor AMY1, CALCR/RAMP1 agonist
- Olcegepant
- Pramlintide Amylin receptor AMY1, CALCR/RAMP1 agonist
- Pramlintide acetate Amylin receptor AMY1, CALCR/RAMP1 agonist
- Rimegepant
- SMC021 Calcitonin receptor agonist